Women's Health contents for HCP's
  • Infertility
    • Fertility and reproductive health: focus on AMH
    • More information
    • News – Infertility
  • Pregnancy
    • Preeclampsia
      • Introduction to preeclampsia
      • Diagnostic pathway for screening, prediction and diagnosis of preeclampsia
      • Treatment
      • Key scientific and clinical evidence
      • NICE guidelines
      • More information
    • News – Pregnancy
  • Cervical Cancer
    • Roche Cervical Cancer portfolio
    • Screen with cobas HPV
    • Triage with CINtec Plus Cytology
    • Diagnose with CINtec Histology
    • More information
    • News – Cervical Cancer
  • Osteoporosis
    • Bone Markers for an improved patient management
    • More information
    • News – Osteoporosis
  • News
  • Search
  • Menu Menu

Cookies list

You are here: Home1 / Cookies list

News

  • International Evidence-based Guidelines for the assessment and management of polycystic ovarian syndrome 2023International Evidence-based Guidelines for the assessment and management of polycystic ovarian syndrome 202331. August, 2023 - 8:36
  • Spremembe in dopolnitve Pravilnika za izvajanje preventivnega zdravstvenega varstva na primarni ravniChanges and Amendments to the Regulation on the Implementation of Preventive Health Care at the Primary Level in Slovenia26. May, 2023 - 9:05
  • Roche Women’s Health Newsletters3. May, 2023 - 15:31
  • Improving cancer screening in the EU24. June, 2022 - 6:53
  • The Value of DiagnosticsCervical Cancer – The value of diagnostics17. June, 2022 - 9:07
All news

Login with Dialog

Login with DiaLog

Contact

Slovenia

Roche farmacevtska družba d.o.o.
Stegne 13g
SI-1000 Ljubljana
Telephone: +386 1 360 26 00
e-mail: slovenija.info@roche.com

Croatia

Roche d.o.o.
Ulica grada Vukovara 269a
10000 Zagreb
Telephone: +385 1 472 23 33
e-mail: croatia.info@roche.com

Disclaimer
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

This web page is not intended for reporting adverse drug reactions and other safety information.

Slovenia
Please report the suspected adverse reactions that you notice during drug therapy in accordance with the Rules on the Pharmacovigilance of medicinal products for human use (Official Gazette of the Republic of Slovenia, No. 57/14 and 27/17), in the way it is published on the website www.jazmp.si.

Roche contacts for collecting safety information regarding Roche medicinal products: slovenia.drugsafety@roche.com.

Croatia
Please report the suspected adverse reactions that you notice during drug therapy in accordance with the Ordinance on Monitoring Adverse Incidents Related to Medical Devices (Official Gazette, no. 125/13) in the way it is published on the website http://www.halmed.hr/

Roche contacts for collecting safety information regarding Roche medicinal products: croatia.drugsafety@roche.com.

Bosnia and Herzegovina
Please report the suspected adverse reactions that you notice during drug therapy in accordance with the Ordinance On Advertising Of Medicinal Products And Medical Devices (Official Gazette, no. 58/12) in the way it is published on the website http://www.almbih.gov.ba/

Roche contacts for collecting safety information regarding Roche medicinal products: bosnia.drugsafety@roche.com.

© 2018 Roche Slovenija :: Production: Votan komunikacije Nastavitve piškotkov | Cookies list | Slovenia: Legal statement, Privacy policy  |  Croatia: Legal statement, Privacy policy
Scroll to top

You are about to leave the Roche website

You are about to leave the Roche website. The website which you intend to visit is operated by a third party. The link to this web site is not offering any representation or warranty for the products and services available on the third party website and is intended solely to grant access to the third party web sites. Do you wish to proceed?

No, close Yes, continue